The effect of plasma cortisol on hippocampal atrophy and clinical progression in mild cognitive impairment
Silke White, René Mauer, Catharina Lange, Olga Klimecki, Willem Huijbers, Miranka Wirth,- Psychiatry and Mental health
- Neurology (clinical)
Abstract
Introduction
Both elevated cortisol and hippocampal volume have been linked to an increased risk for the development of Alzheimer's disease (AD). This longitudinal study assessed the effects of plasma cortisol on hippocampal atrophy and clinical progression rates in patients with mild cognitive impairment (MCI).
Methods
Patients with amnestic MCI (n = 304) were selected from the Alzheimer's Disease Neuroimaging Initiative (ADNI) based on availability of baseline plasma cortisol and hippocampal volume measures, assessed at baseline and during follow‐ups. We investigated associations between plasma cortisol, hippocampal volume, and risk of clinical progression to AD over a study period of up to 100 months (mean follow‐up time 36.8 months) using linear mixed models, Cox proportional hazards models, and Kaplan‐Meier estimators.
Results
Plasma cortisol predicted greater hippocampal atrophy, such that participants with higher cortisol showed faster decline in hippocampal volume over time (interaction: β = ‐0.15, p = 0.004). Small hippocampal volume predicted a higher risk of clinical progression to AD (haard ratio [HR] = 2.15; confidence in terval [CI], 1.64–2.80; p < 0.001). A similar effect was not found for cortisol (HR = 1.206; CI, 0.82–1.37; p = 0.670) and there was no statistical evidence for an interaction between hippocampal volume and cortisol on clinical progression (HR = 0.81; CI, 0.57–0.17; p = 0.260).
Discussion
Our findings suggest that higher cortisol predicts higher hippocampal atrophy, which in turn is a risk factor for progression to AD. Regulation of the hypothalamic‐pituitary‐adrenal axis through stress‐reducing lifestyle interventions might be a protective factor against hippocampal degeneration at the prodromal stage of AD.